Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma
International Journal of Urology · 2025
DOI: 10.1111/iju.70002 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Toru Kanno und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell, Lymph Node Excision, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Objectives
The impact of lymph node dissection (LND) on the efficacy of pembrolizumab in patients with urothelial carcinoma (UC) who develop metastasis after surgery remains unclear. This study aimed to investigate the efficacy of pembrolizumab in patients with metastatic UC who underwent primary tumor resection with LND. Patients and methods This retrospective study included patients who initially underwent radical surgery with or without LND for non‐metastatic UC and later received pembrolizumab for recurrent lesions. Data were collected from a retrospective nationwide Japanese cohort study in patients with metastatic UC treated with pembrolizumab. The primary endpoints were overall response rate (ORR) and overall survival (OS). Multivariate analysis was performed to identify predictors of OS.
Results
A total of 393 patients (273 [69.5%] underwent LND, and 120 (30.5%) did not) were included in this study. The ORRs for patients with and without LND were 30.8% and 27.3%, respectively ( p = 0.460). No significant difference in OS was observed between the two groups ( p = 0.471). Multivariate Cox regression analysis revealed that a neutrophil‐to‐lymphocyte ratio ≥3.0, Eastern Cooperative Oncology Group performance status ≥2, hemoglobin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
- Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Urology, University of Yamanashi, Chuo, Japan.
- Department of Urology, Nagoya University, Nagoya, Japan.
- Department of Urology, Harasanshin Hospital, Fukuoka, Japan.
- Department of Urology, Hokkaido University, Sapporo, Japan.
ORCID-Profile: Toru Kanno, Katsuhiro Ito, Yuki Kita, Akira Yokomizo, Takashige Abe, Ryoichi Saito, Takashi Kobayashi
Zitieren
APA
Kanno, T., Ito, K., Kita, Y., Mochizuki, T., Sano, T., Yokomizo, A., Abe, T., Tsuchihashi, K., Tatarano, S., Inokuchi, J., Takahashi, A., Matsui, Y., Nishiyama, H., Kitamura, H., Saito, R., Kobayashi, T., & Japan Urological Oncology Group (2025). Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma. International Journal of Urology. https://doi.org/10.1111/iju.70002
Vancouver
Kanno T, Ito K, Kita Y, Mochizuki T, Sano T, Yokomizo A, et al. Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma. International Journal of Urology. 2025. doi:10.1111/iju.70002
BibTeX
@article{Kanno2025,
author = {Kanno, Toru and Ito, Katsuhiro and Kita, Yuki and Mochizuki, Takanori and Sano, Tomoyasu and Yokomizo, Akira and Abe, Takashige and Tsuchihashi, Kazunari and Tatarano, Shuichi and Inokuchi, Junichi and Takahashi, Atsushi and Matsui, Yoshiyuki and Nishiyama, Hiroyuki and Kitamura, Hiroshi and Saito, Ryoichi and Kobayashi, Takashi and Japan Urological Oncology Group, Japan Urological Oncology Group},
title = {Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70002}
}
EUVIMED